Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026 BEHoLD Study Group. Sherman M, et al. Among authors: yurdaydin c. Gastroenterology. 2006 Jun;130(7):2039-49. doi: 10.1053/j.gastro.2006.04.007. Gastroenterology. 2006. PMID: 16762627 Clinical Trial.
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Sherman M, et al. Among authors: yurdaydin c. Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323. Hepatology. 2008. PMID: 18537189 Clinical Trial.
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Marcellin P, et al. Among authors: yurdaydin c. Gastroenterology. 2009 Jun;136(7):2169-2179.e1-4. doi: 10.1053/j.gastro.2009.03.006. Epub 2009 Mar 19. Gastroenterology. 2009. PMID: 19303414 Clinical Trial.
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis.
Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Kabaçam G, et al. Among authors: yurdaydin c. Turk J Gastroenterol. 2012;23(5):560-8. doi: 10.4318/tjg.2012.0538. Turk J Gastroenterol. 2012. PMID: 23161302 Free article. Clinical Trial.
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee LJ, Elkhashab M, Berg T, Sporea I, Yurdaydin C, Husa P, Jablkowski MS, Gane E. Fung S, et al. Among authors: yurdaydin c. J Hepatol. 2017 Jan;66(1):11-18. doi: 10.1016/j.jhep.2016.08.008. Epub 2016 Aug 18. J Hepatol. 2017. PMID: 27545497 Free article. Clinical Trial.
189 results